Kidney hope for sickle cell patients fizzles as trial pulled
NCT ID NCT06286046
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This study aimed to see if the drug mitapivat could improve kidney function in people with sickle cell disease and kidney damage. It planned to enroll about 0 participants aged 16 and older with specific types of sickle cell disease. The trial was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.